Repligen's Cash & cash equivalent grew by 6.48 % in the Q3 2026 sequentially, while Current Liabilities decreased, this led to improvement in Repligen's Quick Ratio to 6.87, above Repligen Corp average Quick Ratio.

Within Biotechnology & Pharmaceuticals industry 50 other companies have achieved higher Quick Ratio than Repligen in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 622, from total ranking in the second quarter 2026 at 831.

Explain Quick Ratio?
How much Cash & cash equivalents RGEN�s has?
What are RGEN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/RGEN/financial-strength

https://api.csimarket.com/api/v1/companies/RGEN/fundamentals

https://api.csimarket.com/api/v1/companies/RGEN/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

RGEN Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	12.4 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	15.26 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	6.87	Subscribe	Subscribe	Subscribe	Subscribe
RGEN's Total Ranking	# 622	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-7.86 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	6.48 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 51
Healthcare Sector	# 238
Overall Market	# 647

Quick Ratio Statistics
High	Average	Low
14.37	5.53	1.35
(Sep 30 2019)		(Sep 30 2017)

Financial Statements
Repligen's Current Liabilities	$ 126 Millions	Visit RGEN's Balance sheet
Repligen's Cash & cash equivalent	$ 863 Millions	Visit RGEN's Balance sheet
Source of RGEN's Sales		Visit RGEN's Sales by Geography

Cumulative Repligen's Quick Ratio

RGEN's Quick Ratio for the trailling 12 Months

RGEN Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	3.02 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	10.76 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	6.65	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 3587	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	2.94 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	3.67 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to RGEN Financial Strength Comparisons >> Go to Compare RGEN Quick Ratio to its Competitors

On the trailing twelve months basis RGEN Cash & cash equivalent increased by 15.26 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Repligen's Quick Ratio to 6.65, above RGEN average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 137 other companies have achieved higher Quick Ratio than Repligen. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2696 to 3587.

Explain Quick Ratio?
How much Cash & cash equivalents RGEN�s has?
What are RGEN�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 138
Healthcare Sector	# 858
Within the Market	# 3587

trailing twelve months Quick Ratio Statistics
High	Average	Low
12.3	4.43	1.43
(Jun 30 2020)		(Dec 31 2022)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Crispr Therapeutics Ag	16.12	$ 2,272.548 Millions	$ 140.962 Millions
Imagenebio Inc	15.68	$ 126.597 Millions	$ 8.075 Millions
Inhibikase Therapeutics Inc	14.92	$ 193.321 Millions	$ 12.957 Millions
Aura Biosciences Inc	13.93	$ 297.233 Millions	$ 21.337 Millions
Maze Therapeutics Inc	13.77	$ 389.658 Millions	$ 28.300 Millions
Vor Biopharma Inc	13.25	$ 481.551 Millions	$ 36.344 Millions
Tectonic Therapeutic Inc	13.05	$ 234.666 Millions	$ 17.986 Millions
Beam Therapeutics Inc	12.72	$ 1,043.873 Millions	$ 82.076 Millions
X4 Pharmaceuticals Inc	12.53	$ 187.701 Millions	$ 14.984 Millions
Odyssey Therapeutics, Inc.	12.49	$ 326.001 Millions	$ 26.101 Millions
Solid Biosciences Inc	11.46	$ 348.928 Millions	$ 30.454 Millions
Kalaris Therapeutics Inc	9.73	$ 82.856 Millions	$ 8.514 Millions
Zura Bio Limited	9.22	$ 187.652 Millions	$ 20.349 Millions
Protara Therapeutics Inc	8.83	$ 127.050 Millions	$ 14.391 Millions
Immunovant Inc	6.94	$ 722.274 Millions	$ 104.022 Millions
Repligen Corp	6.87	$ 862.979 Millions	$ 125.686 Millions
Compass Therapeutics Inc	6.69	$ 163.058 Millions	$ 24.368 Millions
Black Diamond Therapeutics Inc	6.62	$ 102.030 Millions	$ 15.405 Millions
Krystal Biotech Inc	6.45	$ 916.484 Millions	$ 142.144 Millions
Voyager Therapeutics Inc	6.35	$ 106.806 Millions	$ 16.813 Millions
Cabaletta Bio Inc	6.33	$ 299.383 Millions	$ 47.332 Millions
Cognition Therapeutics inc	6.00	$ 30.758 Millions	$ 5.128 Millions
Replimune Group Inc	5.57	$ 307.833 Millions	$ 55.271 Millions
Denali Therapeutics Inc	5.42	$ 516.196 Millions	$ 95.258 Millions
In8bio Inc	5.32	$ 13.973 Millions	$ 2.628 Millions
Scholar Rock Holding Corp	5.16	$ 413.599 Millions	$ 80.124 Millions
Revolution Medicines Inc	4.81	$ 3,651.385 Millions	$ 758.773 Millions
Caribou Biosciences Inc	4.71	$ 94.881 Millions	$ 20.144 Millions
Recursion Pharmaceuticals Inc	4.47	$ 549.853 Millions	$ 122.918 Millions
Ginkgo Bioworks Holdings Inc	4.33	$ 285.361 Millions	$ 65.849 Millions

Date modified: 2026-10-31T17:28:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.